Lifecare ASA

Share Issue/Capital Change • Jan 14, 2026

Lifecare ASA: Mandatory notification of trade subscription of shares in rights issue

Lifecare ASA: Mandatory notification of trade subscription of shares in rights issue

Reference is made to the stock exchange announcement published by Lifecare ASA

(the "Company") on 7 January 2026 regarding the commencement of the

subscription period in the partially underwritten rights issue (the "Rights

Issue").

Subscription rights were allocated to existing shareholders as of 2 January

2026 (as registered in the VPS as of 6 January 2026). Each subscription right

entitles the holder to subscribe for and be allocated one (1) new share at the

subscription price in the Rights Issue of NOK 0.50 per share.

Subscribers in the Rights Issue will, without cost, receive warrants in two

series: (a) three (3) warrants for every four (4) new shares allocated to, and

paid by, them in the Rights Issue, which will be exercisable in the exercise

period from 2 March 2026 to 13 March 2026 ("Warrants Series 1"); and (b) three

(3) warrants for every four (4) new shares allocated to, and paid by them, in

the Rights Issue, which will be exercisable in the exercise period from 1 June

2026 to 12 June 2026 ("Warrants Series 2" and together with Warrants Series 1,

the "Warrants"). By subscribing for new shares in the Rights Issue,

subscribers will at the same time subscribe for the corresponding number of

Warrants.

Hannibal Invest AS, a company closely associated with Hans Hekland, board

member of the Company, has subscribed for 200,000 new shares in the Rights

Issue, of which 187,739 new shares have been subscribed through the exercise

of subscription rights, and will as such be allocated to Hannibal Invest AS in

accordance with the terms of the Rights Issue. The remaining 12,261 new shares

subscribed constitute over-subscription, and there can be no assurance that

new shares (or the corresponding number of Warrants as set out below) will be

allocated for such over-subscription.

Further, in accordance with the terms of the Rights Issue, Hannibal Invest AS

has at the same time subscribed for in total 300,000 Warrants, of which 18,391

Warrants relate to over-subscription.

Please see the attached PDMR form for further details.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's focus is to bring the next

generation of Continuous Glucose Monitoring systems to market. Lifecare

enables osmotic pressure as sensing principle. Lifecare's sensor technology is

suitable for identifying and monitoring the occurrence of a wide range of

analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities

Trading Act, §5-12. The information was submitted for publication, through the

agency of the contact persons set out above, at 2026-01-14 14:05 CET.